COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients (rTMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02693743
Recruitment Status : Terminated (Study terminated early due to slow accrual or other non-safety related issues)
First Posted : February 29, 2016
Results First Posted : March 18, 2020
Last Update Posted : April 22, 2020
Information provided by (Responsible Party):
University of Arkansas

Brief Summary:
Suicide was responsible for almost 40,000 deaths in 2011 in America. It is still singularly difficult to predict who is going to commit suicide and how to establish adequate interventions. Growing evidence supports the view that suicide is associated with poor decision making. Suicide is hypothesized to be triggered by stressful situations that create overwhelming psychological pain in an individual who chooses to terminate his/her own life, disregarding all future consequences. We have previously demonstrated rewarding impulsive choice common to both recent suicide attempters and suicidal depressed patients (1). Consistent with these findings, we hypothesize that high frequency repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal cortex will improve impulsive response tendencies as measured by the delay discounting procedure, and this in turn will be associated with a faster resolution of suicidal ideation. To these effects we will be using a randomized control trial of rTMS in adult inpatients at the Psychiatric Research Institute (PRI) hospitalized for acute suicidality. At the conclusion of these studies, we will have tested the value of decision making in the development of suicide ideation and behavior, as well as piloted the use of rTMS in the treatment of these patients.

Condition or disease Intervention/treatment Phase
Suicidal Ideation Device: repetitive transcranial magnetic stimulation (rTMS) Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients
Actual Study Start Date : May 22, 2017
Actual Primary Completion Date : February 28, 2019
Actual Study Completion Date : February 28, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Suicide

Arm Intervention/treatment
Active Comparator: Active rTMS
Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, defined as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a figure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
Device: repetitive transcranial magnetic stimulation (rTMS)
A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.

Sham Comparator: Sham rTMS
Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
Device: repetitive transcranial magnetic stimulation (rTMS)
A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.

Primary Outcome Measures :
  1. Beck Scale for Suicidal Ideation [ Time Frame: Within the 3 days of the TMS trial. ]
    Change in suicidal ideation between baseline assessment and following 3 day TMS trial.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-60 years, of all races and ethnicities;
  • Admitted voluntarily to the adult psychiatric inpatient at PRI;
  • Suffering from a current depressive episode
  • Reason for hospitalization should be a recent suicide attempt or suicidal ideation
  • Current severe suicidal ideation defined by a score >7 on the Beck Scale for Suicidal Ideation
  • Ability to read, write and speak English.

Exclusion Criteria:

  • History of dementia, neurovascular or neurodegenerative conditions
  • Physical disabilities that prohibit task performance (such as blindness or deafness)
  • Choosing to opt out of the research study.
  • Additional exclusion criteria for TMS include the following:

    • a personal history or 1st degree relative with history of epilepsy;
    • a personal history of head injury, aneurysm, stroke, previous cranial neurosurgery, neurological, or migraines;
    • recent use of cocaine or alcohol;
    • ferromagnetic metal implants in the head or neck, active or inactive implants(including device leads), deep brain stimulators, cochlear implants or vagus nerve stimulators;
    • a pacemaker;
    • pregnancy (or the possibility of pregnancy);
    • Medications that lower seizure threshold (bupropion or tricyclic antidepressants, such as thorazine, clozapine, amitriptyline, amoxapine, Norpramin, Sinequan, Tofranil, Pamelor, Vivactil, or Surmontil). Other antidepressant and antipsychotic medications have been deemed exhibit a relatively low seizurogenic potential (Pisani et al. 2002).
    • Patients taking a medication for weight loss and depression called bupropion (Wellbutrin) they will be excluded because it may increase the likelihood of experiencing a seizure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02693743

Layout table for location information
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Layout table for investigator information
Principal Investigator: Pedro L Delgado, MD University of Arkansas
  Study Documents (Full-Text)

Documents provided by University of Arkansas:
Buchwald A. Too soon to say goodbye. 1st ed. New York: Random house; 2006.
Vohs KD, Baumeister R. Escaping the self consumes regulatory resources: a self-regulatory model of suicide. Suicide Science. 2002:33-41.
Hamilton M. Diagnosis and rating of anxiety. The British journal of psychiatry : the journal of mental science. 1969;3:76-9.
Beck AT. Beck Hopelessness Scale. The Psychological Corporation; 1988.
Pascual-Leone A. Handbook of transcranial magnetic stimulation. London New York, NY: Arnold ; Oxford University Press distributor; 2002.

Layout table for additonal information
Responsible Party: University of Arkansas Identifier: NCT02693743    
Other Study ID Numbers: 203818
First Posted: February 29, 2016    Key Record Dates
Results First Posted: March 18, 2020
Last Update Posted: April 22, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by University of Arkansas:
suicide ideation
Additional relevant MeSH terms:
Layout table for MeSH terms
Suicidal Ideation
Self-Injurious Behavior
Behavioral Symptoms